CHRONOTHERAPEUTICS: AN OPTIMIZING APPROACH TO SYNCHRONIZE DRUG DELIVERY WITH CIRCADIAN RHYTHM
Drug delivery systems that precisely control the release rates or target drugs to a specific site have an enormous impact on health care system. In the modern era of treatment many new approaches have been evolved for more efficient administration of drugs. One such approach is the administration of drugs at times at which they are most effective and best tolerated. Chronotherapeutics is the approach in which in vivo availability of drug is timed to match rhythms of disease or disorders in order to optimize therapeutic responses and minimize side effects, which makes it a profound and purposeful delivery of medications in unequal amounts over time (during the 24h). Chrono therapeutic drug delivery systems (ChrDDS) are gaining importance in the field of pharmaceutical technology as these systems reduce dosing frequency, toxicity and deliver drug that matches the circadian rhythm (CR) of that particular disease when the symptoms are maximum to worse. Eventually, the benefit goes to the patient due the compliance and convenience of the dosage form. Various technologies such as time controlled, pulsed, triggered and programmed drug delivery devices have been developed and extensively studied in recent years for chrono pharmaceutical drug delivery. This review specially focuses on ChrDDS and various dosage forms, techniques that are used to target the CRâ€™s of various diseases.
Keywords: Chrono therapeutic drug delivery systems, Circadian rhythms, Therapeutic response, Time controlled, Pulsed, Triggered and programmed technologies.
2. Traynor K, Newton DW, Hrushesky JM, Reiter RJ. â€œA pharmacistâ€™s primer on Chronotherapeuticsâ€. Am Pharm 1992;32:261-9.
3. Reinberg AE. â€œAn experimental basis for chronotherapyâ€, Springer, Heidelberg; 1983. p. 211-63.
4. Reinberg AE. â€œConcepts of circadian chronopharmacologyâ€. Ann NY Acad Sci 1991;618:102-15.
5. Wankhade SA, Rathi AM, Sapkal SB, Babhulkar MW. â€œChrono therapeutic: a new technology in novel drug delivery systemsâ€. Asian J Pharm Inventia 2013;3:26-32.
6. Bhuvnesh, G Gnanarajan, Preeti Kothiyal. â€œReview On: Pulsatile Drug Delivery Systemâ€. J Pharm Sci Res 2009;1:109-15.
7. Rompicharla Bhargavi, Suria Prabha K, Tabasum Md. â€œA comprehensive review of pulsatile drug delivery systemsâ€. Int Res J Pharm 2012;3:106-8.
8. Anamika Singh, Harikesh Dubey, Indu Shukla, Dharmchand P Singh. Pulsatile drug delivery system: an approach of medication according to circadian rhythm. J Appl Pharm Sci 2012;2:166-76.
9. Arora S, Ali J, Ahuja A, Baboota S, Qureshi J. Pulsatile drug delivery systems: an approach for controlled drug delivery. Indian J Pharm Sci 2006;68:295-300.
10. Crison JR, Vieira ML, Kim JS, Siersma C, Amidon GL. Pulse delivery of methylphenidate in dogs using an osmotic drug delivery system. Proc Int Symp Controlled Release Bioact Mater 2001;28:6101.
11. Patrick S, Wong L, Gupta S, Stewart B. Osmotically controlled tablets: In: Rathbone M, Hadgraft J, Roberts M. Modified release drug delivery technology. London: informa Health Care; 2003. p. 113.
12. Sharma S. Osmotic controlled drug delivery system. Latest Rev 2008;6:3.
13. Balaban SM, Pike JB, Smith JP, Baile CA. Osmotically driven delivery devices with pulsatile effect; 1993.
14. Magruder PR, Barclay B, Wong PS, Theeuwes F. Composition Comprising Salbutamol; 1988.
15. Magruder PR, Barclay B, Wong PS, Theeuwes F. Composition comprising a therapeutic agent and a modulating agen; 1989.
16. Gazzaniga A, Sangalli ME, Giordano F. Oral chronotopic and Mac226: drug delivery systems: achievement of time and/or specificity. Eur J Biopharm 1994;40:246-50.
17. Poli S, Busetti C, Moro L. â€œOral pharmaceutical composition for specific colon delivery; 1993.
18. Sangalli ME, Maroni A, Zema L, Busetti C, Giordano F, Gazzaniga A. In vitro and in vivo evaluation of an oral system for time and/or site specific drug delivery. J Controlled Release 2001;73:103-10.
19. Wilding IR, Davis SS, Pozzi F, Furlani P, Gazzaniga A. Enteric coated timed release systems for colonic targeting. Int J Pharm 1994;111:99-102.
20. Sandrine B, Richard H, Elias F. Polymer colon drug delivery systems and their application to peptides, proteins, and nucleic acids. Am J Drug Delivery 2005;34:171-204.
21. Conte U, Maggi L, Torre ML, Giunchedi P, Manna A. Presscoated tablets for time-programmed release of drugs. Biomaterials 1993;14:1017-23.
22. Ozeki Y, Ando M, Watanabe Y, Danjo K. Evaluation of novel one step dry coated tablets as platform for delayedâ€“release tablets. J Controlled Release 2003;95:51-60.
23. Abdul S, Poddar SS. A flexible technology for modified release of drugs: multi layered tablets. J Controlled Release 2004;97:393-405.
24. Krogel I, Bodmeier R. Floating or pulsatile drug delivery systems based on coated effervescent cores. Int J Pharm 1999;187:175-84.
25. Bussemer T, Dashevsky A, Bodmeier R. A Pulsatile drug delivery system based on rupturable coated hard gelatin capsules. J Controlled Release 2003;93:331-9.
26. Ueda Y, Hata T, Yamaguchi H, Kotani M, Ueda S. Development of a novel drug release system, time-controlled explosion system (TES), Part 1: Concept and design. J Drug Targeting 1994;2:35-44.
27. Hata T, Shimazaki Y, Kagayama A, Tamura S, Ueda S. Development of a novel drug delivery system (TES): Part V: animal pharmacodynamic study and human bioavailability study. Int J Pharm 1994;110:1-7.
28. Amidon GL, Leesman GD. â€œPulsatile drug delivery system; 1993.
29. Beckert TE, Pogarell K, Hack I, Petereit HU. Pulsed drug release with film coatings of eudragit and Mac 226; RS 30D. Int Symp Controlled Release Bioact Mater 1999;26:533-4.
30. Narisawa S, Nagata M, Danyoshi C, Yoshino H, Murata K, Hirakawa Y, et al. An organic acid-induced sigmoidal release system for oral controlled-release preparations. Pharm Res 1994;11:111-6.
31. Narisawa S, Nagata M, Hirakawa Y, Kobayashi M, Yoshino H. An organic acid-induced sigmoidal release system for oral controlled release preparations. Part II: permeability enhancement of Eudragit RS coating led by the physicochemical interactions with organic acid. J Pharm Sci 1996;85:184-8.
32. Survase S, Kumar N. Pulsatile drug delivery: current Scenario. Curr Res Inform Pharm Sci 2007;8:27-33.
33. Kikuchi A, Okano T. Pulsatile drug release control using Hydrogel. Adv Drug Delivery Rev 2002;54:53-77.
34. Chein YW. Novel drug delivery system. Edn 2. Vol. II. Marcel Dekker, New York; 1992. p. 139-96.
35. Chien YW. Potential development and new approaches in oral controlled release drug delivery system. Drug Dev Ind Pharm 1983;9:1291-330.
36. Saslawski O, Weigarten C, Beniot JP, Couvereur P. Magnetically responsive microspheres for the pulsed delivery of insulin. Life Sci 1988;42:1521-8.
37. Kulkarni RV, Biswanath SA. Electroresponsive polyacrylamidegrafted-xanthan hydrogels for drug delivery. J Bioact Compat Polym 2009;24:368-84.
38. Qiu Y, Park K. Environment-sensitive hydrogels for drug delivery. Adv Drug Delivery Rev 2001;53:321â€“39.
39. White WB, Mehrotra DV, Black HR, Fakouhi TD. Effects of controlled onset extended release Verapamil on nocturnal blood pressure (dippers versus nondippers)-verapamil study group. Am J Cardiol 1997;80:469-74.
40. Leslie S. The contin delivery system: dosing considerations. J Allergy Clin Immunol 1986;78:768-73.
41. http://www.aptalispharmaceuticaltechnologies.com/tech_diffucap.html [Last accessed on 11 Apr 2012].
42. Rajan K Verma, Sanjay G. Current status of drug delivery technologies and future directions. Pharm Technol Line 2001;25:1-14.
43. http://www.aptalispharmaceuticaltechnologies.com/tech_diffutab. html [Last accessed 11 Apr 2012].
44. Andrea Gazzaniga, Luca Palugan, Anastasia Foppoli, Maria Edvige Sangalli. Oral pulsatile delivery systems based on swellable hydrophilic polymers. Eur J Pharm Biopharm 2008;68:11â€“8.
45. Conte U, Maggi L. Modulation of the dissolution profiles from GeomatrixÂ® multi-layer matrix tablets containing drugs of different solubility. Biomaterials 1996;17:889-96.
46. Conte U, Maggi L, Colombo P, La Manna A. Multi-layered hydrophilic matrices as constant release devices (GeomatrixÂ® systems). J Controlled Release 1993;26:39-47.
47. Elan Corporation. Intestinal protective drug absorption system. US Patent 75111480; 1997.
48. http://www.aptalispharmaceuticaltechnologies.com/tech_minitabs.html. [Last accessed on 11 Apr 2012]
49. http://www.aptalispharmaceuticaltechnologies.com/tech_orbexa.html. [Last accessed on 11 Apr 2012]
50. Dhirendra C Patel, Ritesh B Patel, Gargi B Patel. Recent advance in pulsatile drug delivery system. Recent Pat Drug Delivery Formulation 2009;3:49-63.
51. Parcel P, Vishnupad KS, Venkatesh GM. Timed pulsatile drug delivery systems. US Patent 6,627,2231.
52. www.elan.com/edt/oral control release technology. [Last accessed on 11 Apr 2012].
53. Hradetzky D. Transdermal drug delivery devices for chronotherapy. Med Device Technol 2008;19:45-7.
54. Kato H, Nagata O, Yamazaki M, Suzuki T, Nakano Y. Development of transdermal formulation of tulobuterol for the treatment of bronchial asthma. Yakugaku Zasshi 2002;122:57â€“69.
55. http://www.prnewswire.com/news-releases/Chronotherapeutics-inc-unveils-its-fully functional-miniaturized-and-portable-5th-generation-chronodosetm-prototype-55391282.html. [Last accessed on 11 Apr 2012]
56. Giannos SA, Dinh SM, Berner B. Temporally controlled drug delivery systems. U. S. Patent 6,068,853, 2000.
57. Pednekar P, Parmar C. Chrono pharmaceutical drug delivery systems. An overview. Int J Curr Pharm Res 2011;3:20-6.
58. Santini JT, Cima MJ, Langer R. A controlled release microchip. Nature 1999;397:335-8.
59. Nitin S Satarkar, Zach Hilt J. Magnetic hydrogel nanocomposite for remote controlled pulsatile drug release. J Controlled Release 2008;130:246â€“51.
60. Pednekar P, Parmar C. Chrono pharmaceutical drug delivery systems. An overview. Int J Curr Pharm Res 2011;3:20-6.
61. Rajan K Verma, Sanjay G. Current status of drug delivery technologies and future directions. Pharm Technol Line 2001;25:1-14.